Benedict Osorio - 17 May 2022 Form 4 Insider Report for Provention Bio, Inc.

Role
Chief Quality Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
17 May 2022
Net transactions value
$0
Form type
4
Filing time
18 May 2022, 18:05:26 UTC
Previous filing
20 Jan 2022
Next filing
09 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +9,000 +17% $0.000000 61,000 17 May 2022 Common Stock, par value $0.0001 9,000 $12.89 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 3 filed on December 23, 2021, on August 17, 2020 the Reporting Person was granted a stock option for 100,000 shares of Common Stock, 40,000 of which option shares vest in four equal annual installments commencing on August 17, 2021 and 60,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 9,000 of the 60,000 performance option shares on May 17, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 9,000 option shares.
F2 The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
F3 Represents the 40,000 time-based option shares referred to in footnote (1), 12,000 option shares which previously vested upon the satisfaction of certain performance milestones, and the 9,000 vested performance option shares that vested on May 17, 2022.